2025 · 4th Quarter (Oct 1 - Dec 31)

ALNYLAM PHARMACEUTICALS, INC.

Filed by ALNYLAM PHARMACEUTICALS, INC..

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 20, 2026
Income: Not reported
Expenses: $390,000.00
Registrant: ALNYLAM PHARMACEUTICALS, INC.
Client: ALNYLAM PHARMACEUTICALS, INC.
Filing UUID: b88a93a2-1a18-4e80-a9df-3a3377b5eb68
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing.

MMM · Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act

Literal federal measure citations: HR.4993

TRD · Trade (domestic/foreign)

Issues relating to supply chain tariffs

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.